Overview

A Study of DS-1471a In Subjects With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This first-in-human (FIH) study will assess the safety, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of DS-1471a in participants with advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.